Early warning HPV+ head & neck and anal cancer recurrence, delivered by a simple blood draw.
With cancer, there are often more questions than answers – but here’s what we know about the risk of HPV+ head & neck and anal cancer recurrence:
NavDx is the first and most clinically validated blood test that aids in the early detection of HPV-driven cancer
Detecting recurrence early, when disease burden is low, may improve your chances of long-term survivorship1,2
Symptoms of cancer recurrence can be delayed or subtle
Imaging and clinical exams can miss early signs of head & neck cancer and anal cancer recurrence3,4
Within 5 years of treatment, cancer comes back for up to 1 in 4 HPV+ head & neck cancer patients (recurrence)5,6
Up to one half of first recurrences for head & neck cancer are in a new part of the body (distant metastasis)6
Ask. Test. Know.
Published studies of people who received treatment for HPV+ cancer show NavDx testing accurately and reliably predicted when cancer returned.7,8,4
For patients with HPV+ head & neck cancer
≥ 95%
of people with one positive test had cancer recur
≥ 98%
of people who routinely tested negative had no cancer recurrence
For patients with HPV+ anal cancer
≥ 96%
of people with one positive test had cancer recur
≥ 92.5%
of people who routinely tested negative had no cancer recurrence